Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A combination of two targeted therapies led to long-lasting remission in a small study of patients with hairy cell leukemia.
Tecentriq plus two targeted medications extended progression-free survival by 4.5 months.
An ongoing study is assessing pediatric and young adult cancers that did not respond to initial treatments.
FDA expands approval of Zelboraf (vemurafenib) to treat certain adult patients with Erdheim-Chester Disease, a rare cancer of the blood.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.